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Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in infants and the elderly.
RSV vaccine development has been hampered by results of clinical trials in the 1960s, when formalin-
inactivated whole-RSV preparations adjuvated with alum (FI-RSV) were found to predispose infants for
enhanced disease following subsequent natural RSV infection. We have reproduced this apparently immuno-
pathological phenomenon in infant cynomolgus macaques and identified immunological and pathological
correlates. Vaccination with FI-RSV induced specific virus-neutralizing antibody responses accompanied by
strong lymphoproliferative responses. The vaccine-induced RSV-specific T cells predominantly produced the
Th2 cytokines interleukin-13 (IL-13) and IL-5. Intratracheal challenge with a macaque-adapted wild-type RSV
3 months after the third vaccination elicited a hypersensitivity response associated with lung eosinophilia. The
challenge resulted in a rapid boosting of IL-13-producing T cells in the FI-RSV-vaccinated animals but not in
the FI-measles virus-vaccinated control animals. Two out of seven FI-RSV-vaccinated animals died 12 days
after RSV challenge with pulmonary hyperinflation. Surprisingly, the lungs of these two animals did not show
overt inflammatory lesions. However, upon vaccination the animals had shown the strongest lymphoprolifera-
tive responses associated with the most pronounced Th2 phenotype within their group. We hypothesize that an
IL-13-associated asthma-like mechanism resulted in airway hyperreactivity in these animals. This nonhuman
primate model will be an important tool to assess the safety of nonreplicating candidate RSV vaccines.
Respiratory syncytial virus (RSV) is a member of the family
Paramyxoviridae, genus Pneumovirus (3). While associated with
relatively mild upper respiratory tract disease in immunocom-
petent adults, RSV infection is a major cause of severe lower
respiratory tract disease in infants, immunocompromised indi-
viduals, and the elderly (7). No vaccine against this important
pathogen is currently licensed (5). Three major obstacles ham-
per the development of a safe and effective RSV vaccine. First,
the highest RSV-related morbidity and mortality are seen in
infants below 6 months of age. A vaccine would therefore have
to be effective in the presence of maternally derived RSV-
specific virus-neutralizing (VN) antibodies and in children with
a relatively immature immune system. Second, natural RSV
infection does not induce sustained protective immunity.
Therefore, a vaccine should ideally induce a better immune
response than natural infection. Both points argue against a
classical live attenuated vaccine and favor a subunit vaccine
approach. However, development of nonreplicating RSV vac-
cines has been seriously hampered by a third complication.
During vaccine trials in the 1960s, experimental formalin-in-
activated whole-RSV (FI-RSV) vaccines were found to predis-
pose infants to enhanced pulmonary disease upon subsequent
RSV infection (17). Studies using murine models of RSV in-
fection have demonstrated that alum-adjuvated FI-RSV is a
strong inducer of Th2 cells, which proved to be the most
important mediators of immunological hypersensitivity (23).
However, histopathological characterization of FI-RSV-medi-
ated enhanced disease by using other animal models has shown
that patterns of inflammation may vary substantially (10, 33),
and the relevance of the different animal models continues to
be subject of debate (32).
Hypersensitivity related to vaccination with formalin-inacti-
vated vaccines is not a unique phenomenon for RSV; it has
also been reported for measles virus (MV), another member of
the Paramyxoviridae family, which is not antigenically related
to RSV. Vaccination with FI-MV predisposed infants for atyp-
ical measles upon natural MV infection. This syndrome was
characterized by high fever, pneumonia, abnormal rash, and
lymphadenopathy (9). It is interesting that FI-RSV-induced
hypersensitivity was observed in a majority of vaccinees during
the first RSV season after vaccination, whereas atypical mea-
sles was observed in a minority of the vaccinees and only years
after FI-MV vaccination. In contrast to what was found for
RSV infection, low levels of MV-specific VN antibodies confer
complete protection against measles. Therefore, susceptibility
to atypical measles in an FI-MV-vaccinated subject will most
probably require the waning of humoral immunity in the pres-
ence of retained MV-specific cellular immunity (8). Due to the
lack of a suitable MV model for small laboratory animals, few
studies to clarify the underlying mechanism of atypical measles
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have been performed. However, the recent reproduction of
atypical measles in a rhesus macaque model pointed to a mech-
anism of immune complex formation and Th2-mediated eosin-
ophilic hypersensitivity responses (28, 29). It may be specu-
lated that similar aberrant immune responses, elicited by either
FI-RSV or FI-MV, result in distinct clinical syndromes, deter-
mined by the distribution of viral antigens in tissue upon nat-
ural infection with these viruses (11).
Studies of FI-RSV-related immunopathogenesis in rodent
models have contributed to our understanding of the underly-
ing mechanisms. However, there are important differences be-
tween rodent and primate immune systems. Therefore, vacci-
nation-and-challenge models for nonhuman primates are
important for additional mechanistic studies, as well as for the
evaluation of the efficacy and safety of candidate RSV vac-
cines. Several monkey species have been shown to be suscep-
tible to RSV infection (1, 35, 41). Studies focusing on the
histopathology of FI-RSV-related enhanced pulmonary dis-
ease in African green monkeys (Cercopithecus aethiops) (16)
and in bonnet monkeys (Macaca radiata) (30) have yielded
largely conflicting data.
We have previously developed a measles vaccination-and-
challenge model for cynomolgus macaques (Macaca fascicu-
laris), which was used for preclinical testing of the safety and
efficacy of candidate measles vaccines (36, 38, 39). The avail-
ability of macaque-specific immunological reagents allows de-
tailed studies of the virus-specific immune response in these
animals. Here, we have used the same species to reproduce
FI-RSV-mediated enhanced disease, with FI-MV-immunized
animals as a control group. We characterized the RSV-specific
humoral and cellular immune responses upon vaccination and
challenge to identify correlates of immunopathology.
MATERIALS AND METHODS
Vaccine preparations. RSV (Long strain) was grown on HEp-2 cells and
harvested at an early stage of the cytopathic effect. Supernatant was centrifuged
(15 min, 1,500  g) to remove cellular debris, and subsequently the virus was
pelleted by ultracentrifugation (Beckman; SW28; 4 h at 25,000 rpm). The pellet
was resuspended in TEN buffer (20 mM Tris-HCl, 1 mM EDTA, 0.15 M NaCl
[pH 7.8]). MV antigen (Edmonston strain; produced on Vero cells) was kindly
provided by R. S. van Binnendijk (Bilthoven, The Netherlands). Both virus
preparations were dialyzed against TEN buffer, adjusted to a protein concentra-
tion of 1 mg/ml, and inactivated by addition of 37% formalin (1:4,000; 3 days at
37°C). The final preparations, which did not contain infectious virus as shown by
cell culture, were adjusted to a protein concentration of 0.2 mg/ml and frozen in
aliquots at 70°C.
A vaccine dose was prepared by mixing FI-RSV or FI-MV (10 g of total
protein) with 1 ml of Adju-Phos (kindly provided by Superfos Biosector, Fred-
erikssund, Denmark) and incubating the mixture for 30 min at room tempera-
ture. The vaccine was administered intramuscularly in the gluteal muscle in two
0.5-ml doses divided over the two legs.
Study design. In a first experiment, eight infant cynomolgus macaques were
vaccinated with either FI-RSV (animals RS1 to -4) or FI-MV (animals MV1 to
-4). All animals received three vaccinations with 4-week intervals. EDTA-blood
samples were collected every 2 weeks. Approximately 3 months after the third
vaccination, all animals were challenged with RSV. Subsequently, five more
infant cynomolgus macaques were vaccinated by using the same materials and
experimental design; three received FI-RSV (animals RS5 to -7) and two re-
ceived FI-MV (animals MV5 and -6). During this last experiment, one animal of
each group was sacrificed for histopathological analysis at days 7 (animals RS5
and MV5) and 13 (animals RS7 and MV6) after challenge.
All animals were between 5 and 12 months of age at the moment of first
vaccination, with the exception of MV1, which was 19 months old. During the
vaccination periods the animals were housed in groups with their mothers.
During the challenge period the animals were housed in smaller standard cages
(three or four animals per cage). The animal study was approved by the Local
Animal Ethics Committee of the Erasmus MC, Rotterdam, The Netherlands,
and was carried out in accordance with animal experimentation guidelines.
Virus neutralization. Virus neutralization assays were carried out as previously
described (31, 36). Briefly, twofold serial dilutions of heat-inactivated (30 min,
56°C) macaque EDTA-plasma samples were tested for their ability to neutralize
100 50% tissue culture infectious doses (TCID50) of RSV (Long strain) or MV
(Edmonston strain). The VN titer was defined as the reciprocal of the plasma
dilution at which 50% of the wells showed cytopathic effect, as calculated from
triplicate measurements by the method of Reed and Muench (34).
Lymphoproliferation. For production of antigens for in vitro stimulations,
RSV (Long strain) and MV (Edmonston strain) were grown in Vero cells. After
clarification the virus was pelleted by ultracentrifugation and resuspended in
RPMI 1640 medium and inactivated with -propiolactone (BPL; Sigma-Aldrich,
St. Louis, Mo.). A cell control antigen was produced by processing freeze-thawed
Vero cells in an identical manner.
Macaque peripheral blood mononuclear cells (PBMC) were isolated by den-
sity gradient centrifugation and resuspended in RPMI 1640 medium supple-
mented with 10% heat-inactivated fetal bovine serum and 1% heat-inactivated
pooled macaque serum. PBMC were cultured in 96-well round-bottom plates (2
 105 cells in 200 l per well) in the presence of BPL-RSV, BPL-MV, or
BPL-Vero antigen at previously determined optimal concentrations. Each lym-
phoproliferation assay was carried out in duplicate, and the resulting culture
supernatants (125 l per well) were harvested after 3 and 5 days, respectively,
and frozen. The supernatant was replaced with 75 l of culture medium, 3H-
labeled thymidine (0.5 Ci per well) was added, and cell-associated radioactivity
was measured the following day.
Cytokine ELISAs. Macaque cytokines (interleukin-2 [IL-2], IL-4, IL-5, IL-10,
IL-13, and gamma interferon [IFN-]) were measured in culture supernatants by
macaque-specific enzyme-linked immunosorbent assay (ELISA) systems (U-
Cytech, Utrecht, The Netherlands) in accordance with the manufacturer’s in-
structions. IL-2 and IFN- were measured in supernatants harvested after 3 days
of culture, while IL-4, IL-5, IL-10, and IL-13 were measured in supernatants
harvested after 5 days of culture.
Challenge virus. A non-tissue-culture-adapted wild-type RSV A strain (nasal
lavage of an infant hospitalized with RSV in 1996) was passaged in an RSV-
seronegative cynomolgus macaque. Virus could be reisolated from throat swab
samples between days 4 and 9 after infection and from a bronchoalveolar lavage
(BAL) sample collected 7 days after challenge, but viral titers remained low. In
an attempt to achieve higher titers, a second macaque was first immunocompro-
mised by intramuscular administration of rabbit anti-human thymocyte globulin
(ATG; National Institute of Public Health and the Environment, Bilthoven, The
Netherlands; 80 mg/kg of body weight). Two days after ATG administration,
almost all lymphocytes had been depleted from peripheral blood, as measured by
a routine hematology analyzer (Sysmex; Myco Instrumentation Source, Renton,
Wash.). At this point the animal was inoculated with a positive throat swab
sample and a BAL sample from the first animal (intranasally and intratracheally,
respectively). The total challenge dose as estimated from isolations on HEp-2
cells was 2  103 TCID50. ATG administration was continued at days 0, 2, and
6 after infection. RSV could be reisolated over a prolonged period of time (until
day 21 after infection), but virus titers still remained relatively low. Pooled throat
swab samples of this animal collected 6, 9, and 12 days after infection were used
to inoculate another ATG-treated cynomolgus macaque with virtually identical
results. Virus could be reisolated until day 26 after infection, but titers remained
below 104 TCID50 per ml. An isolate from BAL cells of the third monkey was
passaged three times in vitro in tertiary cynomolgus macaque kidney cells and
subsequently aliquotted and stored at 135°C. The titer of this challenge stock
as measured on HEp-2 cells was 2.4  106 TCID50 per ml. The challenge virus
stock (as well as the FI-RSV and FI-MV preparations) was checked by reverse
transcription PCR (RT-PCR) for the presence of coronavirus, enterovirus, hu-
man metapneumovirus, influenza A virus, influenza B virus, and rhinovirus
genomic sequences, which could not be demonstrated.
Challenge. The RSV challenge virus was thawed, sonicated in a cup sonicator
for 3 min, and diluted in phosphate-buffered saline (PBS; 1 in 7.5). Subsequently,
3 ml (approximately 106 TCID50) was inoculated intratracheally, just below the
larynx. EDTA-blood samples were collected at days 0, 6, 13, 17, and 22 after
challenge for collection of plasma and PBMC. BAL samples were collected 6
days before challenge and at days 3, 6, 9, and 13 after challenge. Chest X-ray
photographs were made at days 0, 3, 6, and 9 after challenge, and animals RS1
and RS2 were given chest X rays at day 12 after challenge.
BALs. BAL samples were collected by intratracheal infusion and subsequent
recovery of 10 ml of PBS with a flexible catheter (Cordis). BAL samples were
pelleted, resuspended in PBS, and counted. For RT-PCR, 5  105 BAL cells
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were frozen as a dry pellet at 70°C. Cytospin slides were later stained (May-
Gru¨nwald-Giemsa), and differential cell counts were obtained by light micros-
copy, with 1,000 cells per slide counted.
Semiquantitative RT-PCR. RNA from 5  105 BAL cells was isolated with the
High Pure viral RNA kit (Roche Diagnostics, Almere, The Netherlands). Ten-
fold dilutions (100 to 104) were prepared in RNase-free water, and RT-PCR
was performed using a single-tube reaction. The forward primer was 5-TTAA
CCAGCAAAGTGTTA-3 (RSV fusion protein gene positions 567 to 584), and
the reverse primer was 5-TTTGTTATAGGCATATCATTG-3 (complementa-
ry to positions 808 to 788). PCR products were hybridized with a 32P-labeled
oligonucleotide probe (5-GACTACTAGAGATTACCAGGG-3; F gene posi-
tions 697 to 711). A positive RT-PCR was defined as an amplified fragment of
the correct size (243 bp) which hybridized with the specific probe. Results are
shown as the highest RNA dilution at which the RT-PCR was still found positive.
Pathology. Necropsy samples were stored in 10% neutral-buffered formalin
(lungs after inflation with formalin), embedded in paraffin, sectioned at 5 m,
and stained with hematoxylin and eosin. For quantification of eosinophils in
different parts of the respiratory tract, cells in 10 arbitrarily chosen high power
fields (40 objective) were counted.
Statistical analysis. Data were analyzed by using a mixed-model analysis of
variance after log transformation of the dependent variable (see Fig. 4) or by
using the Wilcoxon matched-pair signed-rank test (see Fig. 2 and 5).
RESULTS
Virus-specific immune responses after vaccination. Infant
macaques were immunized three times with FI-RSV (n 7) or
as a control with FI-MV (n  6) formulated in alum. Virus-
specific VN antibody responses in both groups were measured,
and peak titers in FI-RSV-vaccinated animals (range, 102 to
103) were lower than those in FI-MV-vaccinated animals
(range, 104 to 105; Fig. 1A and D, respectively). In most FI-
RSV-vaccinated animals peak titers were reached after the
third vaccination, while the highest titers induced by FI-MV
were reached after the second vaccination. No cross-reactive
VN antibody responses in the FI-RSV- or FI-MV-vaccinated
animals were observed (Fig. 1B and C, respectively). In the
FI-RSV-vaccinated animals more than in the FI-MV-vacci-
nated animals, HEp-2 cell- or Vero antigen-specific plasma
antibodies were detected by ELISA (results not shown).
PBMC of macaques vaccinated with FI-RSV demonstrated
strong proliferative responses after in vitro stimulation with
BPL-inactivated RSV antigen (Fig. 2A). However, these re-
sponses were not significantly higher than those observed after
stimulation with BPL-MV (Fig. 2B), BPL-Vero antigen (Fig.
2C), or medium alone (not shown). In most FI-RSV-vacci-
nated animals slightly higher proliferative PBMC responses
were observed upon stimulation with BPL-RSV, suggesting
that both RSV-specific and nonspecific responses were
present. In contrast, PBMC of the FI-MV-vaccinated animals
showed strong proliferative responses to stimulation with
BPL-MV (Fig. 2E), which were significantly higher than those
observed after stimulation with BPL-RSV (Fig. 2D) or BPL-
Vero antigen (Fig. 2F; P 	 0.05). In both groups the highest
lymphoproliferative responses were observed after the third
vaccination.
Supernatants of PBMC collected 3 weeks after the third
vaccination and stimulated in vitro with BPL-RSV or BPL-MV
were used to measure cytokine levels. In the FI-RSV-vacci-
nated animals the predominant cytokines measured upon in
vitro stimulation with BPL-RSV were IL-13, IL-5, and IL-2,
although PBMC of two animals also produced IFN- (Fig.
3A). The specificity of these responses was illustrated by the
observation that cytokine levels in supernatants of the same
FIG. 1. RSV-specific (A and C) and MV-specific (B and D) VN antibody responses measured in plasma samples of macaques vaccinated with
FI-RSV (A and B) or FI-MV (C and D). Arrows, times of vaccination; asterisks, times of RSV challenge. Symbols represent the titers in the
individual animals, while lines connect the geometric means of the groups over time. Animals RS1 to RS6 and MV1 to MV6 are represented
shaded and open circles, squares, triangles, diamonds, and hexagons, respectively. Animal RS7 is represented by a shaded circle with a plus.
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PBMC stimulated in vitro with BPL-MV were low or unde-
tectable (Fig. 3B). The inverse pattern was observed for the
PBMC cultures of FI-MV-vaccinated animals, which showed
significant IL-13, IL-5, and IL-2 responses (and IFN- re-
sponses in two animals) upon in vitro BPL-MV stimulation
(Fig. 3D) but no detectable cytokine production upon in vitro
BPL-RSV stimulation (Fig. 3C).
RSV challenge. Three months after the last vaccination all
animals were challenged intratracheally with 106 TCID50 of a
macaque-adapted wild-type RSV strain. At that point, all FI-
RSV-vaccinated animals still had RSV-specific VN antibody
titers ranging from 30 to 1,500 (Fig. 1A). With our experimen-
tal setup, it proved difficult to detect clinical symptoms. Res-
piration frequencies were measured at each sampling point
after catching, but these proved to be strongly influenced by
capture-induced stress and showed no differences between the
groups. Cyanosis was never observed, but abnormal breathing
in some animals was found by auscultation. Oxygen saturation
was measured for five animals and was found to be reduced on
days 3, 6, and 9 after challenge (data not shown). Although
virus isolations from throat swabs and BAL samples on HEp-2
cells were attempted, little or no RSV was reisolated (data not
shown). Semiquantitative RT-PCR on BAL cells indicated that
pulmonary viral loads of the FI-RSV-vaccinated animals were
between 1 and 2 log units lower than those in the FI-MV-
vaccinated animals (P 	 0.01; Fig. 4A and B, respectively).
Hypersensitivity in FI-RSV-vaccinated macaques induced
by RSV challenge. Phenotypic analysis of BAL cells collected
at different time points after RSV challenge demonstrated
infiltration of eosinophils in six out of seven FI-RSV-vacci-
nated monkeys, compared to none of the six FI-MV-vaccinated
control animals (P 	 0.01; Fig. 4C and D, respectively).
This apparent hypersensitivity response was associated with
a rapid boosting of the primed Th2 responses, as illustrated by
the significantly increased levels of IL-13 in supernatants of in
vitro-BPL-RSV-stimulated PBMC of the FI-RSV-vaccinated
macaques collected on day 6 after challenge compared to those
in supernatants collected on day 0 (Fig. 5A; P 	 0.05). These
cytokines were not detected in supernatants of similarly stim-
ulated PBMC from the FI-MV-vaccinated macaques (Fig. 5B
FIG. 2. Proliferative PBMC responses of macaques vaccinated with FI-RSV (A to C) or FI-MV (D to F) after in vitro stimulation with
BPL-RSV (A and D), BPL-MV (B and E), or BPL-Vero antigen (C and F). Arrows, times of vaccination; asterisks, times of RSV challenge.
Symbols represent the means of the individual animals (the correlation between symbols and animals is the same as that for Fig. 1), while lines
connect the geometric means of the groups over time.
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and D). IL-13 and to a lesser extent IL-5 were also detected in
PBMC from the FI-RSV-vaccinated animals stimulated in
vitro with BPL-MV and BPL-Vero antigen and collected on
day 6 after challenge (Fig. 5A and C) but not in PBMC from
the FI-MV-vaccinated animals (Fig. 5B and D), indicating an
in vivo priming of the cells producing these Th2 cytokines in
the first group of animals. No significant differences between
the two groups in IFN- levels in the supernatants of PBMC
cultures collected 6 days after challenge were found (Fig. 5E
and F).
Histopathological characterization of hypersensitivity re-
sponses. To characterize the pulmonary histopathology asso-
ciated with the eosinophilia observed in BAL samples of the
FI-RSV-vaccinated animals, animals of each group were sac-
FIG. 3. Cytokine levels in supernatants of PBMC collected from macaques 3 weeks after the third vaccination with FI-RSV (A and B) or FI-MV
(C and D) and stimulated in vitro with BPL-RSV (A and C) or BPL-MV (B and D). The cytokines measured are indicated on the x axis, and levels
are presented above the detection limits. Symbols represent the measurements of the individual animals (the correlation between symbols and
animals is the same as that for Fig. 1), while horizontal lines represent the geometric mean values for the groups.
FIG. 4. Semiquantitative RSV-specific RT-PCR signals (A and B) and percentages of eosinophils (C and D) in BAL samples collected at
different time points after RSV challenge. Symbols represent the measurements of the individual animals (the correlation between symbols and
animals is the same as that for Fig. 1), while lines connect the geometric means of the groups over time. Both parameters were significantly different
between the two groups (mixed analysis of variance; P 	 0.01).
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rificed on day 7 (animals MV5 and RS5) and day 13 (animals
MV6 and RS7) after challenge. In the FI-RSV-primed animals
(RS5 and RS7), but not in the FI-MV-primed animals, marked
eosinophilic tracheobronchitis and bronchiolitis, characterized
by diffuse infiltration of mainly eosinophils and some neutro-
phils in the epithelium and submucosa, were found (Fig. 6A),
with intercellular edema and disturbance of the histological
architecture. In addition, a focal-to-diffuse eosinophilic periar-
teritis of the pulmonary arteries was observed. Quantification
of eosinophil densities in different parts of the respiratory tract
showed significantly higher numbers of eosinophils in the FI-
RSV-primed animals than in the FI-MV-vaccinated animals,
with the highest numbers found in the walls of bronchi and
bronchioles and fewer found in the alveolar lumina (Fig. 6E to
G). Irrespective of their vaccination histories, all four eutha-
nized animals had multifocal-to-locally extensive bronchoint-
erstitial pneumonia characterized by multifocal epithelial ne-
crosis and the presence of macrophages and neutrophils in the
alveolar lumina (Fig. 6B). In addition, multinucleated syncytial
cells and intracytoplasmic inclusion bodies characteristic of
RSV infection were present in all four animals (Fig. 6C and D,
respectively). These lesions were less extensive and more
chronic in the animals euthanized 13 days after challenge,
indicative of a resolving infection.
Two FI-RSV-immunized animals (RS1 and RS2) were
found in a moribund state 12 days after challenge. No infil-
trates were visible by chest X-ray photography, but both ani-
mals showed a clear pulmonary hyperinflation (as shown for
animal RS2 in Fig. 6H and I). One of the animals died, while
the other had to be euthanized. No abnormalities were found
in the lungs of these animals by necropsy and histopathological
examination. However, minor lesions may have been masked
due to suboptimal fixation of the tissue specimens. It is note-
worthy that after vaccination these two animals had the highest
vaccine-induced lymphoproliferative responses (Fig. 2A to
2C), which were of the most pronounced Th2 phenotype in this
group (high IL-13 and IL-5 production in the absence of de-
tectable IFN-; Fig. 3A). Average pulmonary viral loads mea-
sured by RT-PCR analysis in these two animals were not di-
vergent (Fig. 4A), but the percentages of eosinophils in their
BAL cells were lower than average (RS1) or virtually unde-
tectable (RS2; Fig. 4C).
FIG. 5. IL-13 (A and B), IL-5 (C and D), and IFN- (E and F) levels in culture supernatants of PBMC collected from macaques vaccinated
with FI-RSV (A, C, and E) or FI-MV (B, D, and F) at days 0 and 6 after RSV challenge (indicated on the x axes). PBMC were stimulated in vitro
with BPL-RSV, BPL-MV, or BPL-Vero antigen as indicated. Symbols represent the measurements of the individual animals (the correlation
between symbols and animals is the same as that for Fig. 1), while horizontal lines represent the geometric mean values of the groups.
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DISCUSSION
Infant cynomolgus macaques were immunized with FI-RSV
formulated in alum and subsequently challenged intratrache-
ally with RSV. Infant macaques immunized with FI-MV were
used as controls. Animals of both groups developed a multi-
focal bronchointerstitial pneumonia with characteristic
multinucleated syncytial cells, but only the FI-RSV-immunized
animals developed a superimposed diffuse eosinophilic tra-
cheobronchitis and bronchiolitis. Two of the seven FI-RSV-
immunized animals, which had the most prominent Th2 re-
sponses upon vaccination, developed pulmonary hyperinflation
and died 12 days after challenge. Surprisingly, limited and
incomplete study of the lungs of these two animals did not
show obvious inflammatory lesions.
Characterization of the vaccine-induced T-cell immune re-
sponses indicated that vaccination with FI-RSV induced both
virus-specific and nonspecific immune responses, while vacci-
nation with FI-MV induced largely virus-specific responses.
This suggests that our FI-RSV preparation, more than our
FI-MV preparation, contained immunogenic cellular or serum
proteins. It has been found that formalin-inactivated mock
antigen can predispose rodents to hypersensitivity upon RSV
challenge, supposedly as a result of nonviral proteins present in
the challenge stock (2, 27). We therefore cannot exclude the
possibility that the immunopathology observed in FI-RSV-
primed and RSV-challenged animals was at least in part due to
recall of these responses by nonviral proteins present in the
challenge stock.
Both FI-RSV and FI-MV vaccination induced strong lym-
phoproliferative responses, which is in accordance with obser-
vations in infants in vaccine trials in the 1960s (18, 19). Mea-
surement of cytokine levels in culture supernatants showed
that both vaccine preparations induced virus-specific T cells,
which predominantly produced IL-13, IL-5, and IL-2 upon
stimulation with BPL-inactivated virus antigens. Although
IL-13 was detected in supernatants of PBMC stimulated with
the homologous antigen in both groups of animals after vac-
cination, RSV challenge boosted these responses only in the
FI-RSV group.
IL-13 is thought to play a key role in the development of
asthma and airway hyperreactivity (AHR) (4, 13, 42), while
IL-5 is a hematopoietic growth factor responsible for growth
and differentiation of eosinophils (12). Both IL-13 and IL-5
have also been implicated in FI-RSV-mediated hypersensitiv-
ity in BALB/c mice (15, 40). In addition, FI-RSV priming and
subsequent RSV challenge have been found to exacerbate
AHR in mice (26), which was probably mediated by IL-13 (20,
25, 37). IL-13 is also a down-regulating factor of macrophage
function, in particular production of IL-12 (6), which could
explain the previously observed altered IL-12 synthesis in ma-
caques primed with FI-MV and challenged with wild-type MV
(29).
FIG. 6. (A) Diffuse infiltration of eosinophils (arrows) in the bronchial wall, as seen in the FI-RSV-primed monkeys euthanized at 7 or 13 days
after challenge; (B to D) multifocal infiltration of inflammatory cells in the pulmonary parenchyma (B) with multinucleated syncytial cells (arrow;
C) and eosinophilic intracytoplasmic inclusion bodies (arrows; D) characteristic of RSV infection, as seen in all four animals euthanized at 7 or
13 days after challenge irrespective of their vaccination history; (E to G) quantification of eosinophil numbers in bronchial (E) and bronchiolar
(F) walls and in alveolar lumina (G) of FI-MV-primed (blue bars) and FI-RSV-primed (red bars) animals euthanized at 7 (solid bars) or 13
(hatched bars) days after challenge; (H and I) chest X rays of one of the FI-RSV-primed animals that died at day 12 after challenge, showing the
normal image at day 9 (H) and pulmonary hyperinflation at day 12 (I). Bright vertical marks, identification chip; hpf, high-power field; SD, standard
deviation.
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Why did two of the FI-RSV-vaccinated animals develop
pulmonary hyperinflation 12 days after challenge in the ab-
sence of cellular infiltrates in their lungs? The timing is in
agreement with a T-cell- and cytokine-mediated mechanism.
We hypothesize that the underlying mechanism was not rem-
iniscent of a normal RSV bronchiolitis but rather resulted from
an asthma-like pathogenesis associated with a smooth muscle-
mediated airway obstruction (14, 21). Remarkably, the two
animals that died in our study had almost undetectable (RS2)
or relatively low (RS1) eosinophil counts in their BAL cells.
The highly skewed Th2 responses in these two animals may
have resulted in a distinct type of antiviral immune response
compared to those of the other five FI-RSV-immunized mon-
keys. This biological variation can probably be attributed to the
use of outbred non-specific-pathogen-free animals and could
also be expected in humans.
We observed significant eosinophilia in the BAL samples
obtained from six out of seven FI-RSV-primed macaques upon
RSV challenge. Eosinophils have also been described as an
important marker of FI-RSV-mediated enhanced disease in
BALB/c mice (23), but in cotton rats and cattle the major
lesions observed were rather characterized by the presence of
neutrophils (10, 33). In the two infants who died in 1967 the
major inflammatory cells were also neutrophils (32), which
favors the use of the cotton rat and bovine models. However,
in our study the two macaques that died may not have been
representative of the whole group in their histopathological
presentation and did not show substantial inflammation at the
moment of death. The availability of immunological reagents
to study the RSV-specific immune response both in cattle and
in cotton rats will, it is hoped, shed more light on the patho-
genesis of the enhanced disease in these species, allowing com-
parisons with the mouse model and the present study.
Semiquantitative RSV-specific RT-PCR on BAL samples
suggested that the viral loads in the lungs of the FI-RSV-
vaccinated animals were 1 to 2 log units lower than those in the
FI-MV-vaccinated animals. This is in accordance with virus
shedding data for FI-RSV-vaccinated African green monkeys
(16) but is in contrast to the results of a recent study of FI-RSV
immunization in bonnet monkeys, which showed increased
replication of RSV following challenge (30). However, in the
latter study FI-RSV vaccination resulted in low lymphoprolif-
erative and VN antibody responses, while in our study these
responses were more pronounced. VN antibodies have been
shown to confer protection against RSV lower respiratory tract
infection (7), so in our study the FI-RSV-induced immune
responses may well have resulted in a combination of partial
protection and predisposition for immunopathology. Whether
virus replication is reduced or increased may be determined by
the balance between the antiviral effects of the RSV-specific
immune response on the one hand and the numbers and phe-
notype of infiltrating cells promoting virus replication on the
other.
In conclusion, we developed an FI-RSV immunopathology
model for infant cynomolgus macaques and identified virus-
specific IL-13 and IL-5 production upon vaccination as the
immunological correlate of hypersensitivity responses upon in-
tratracheal RSV challenge. The observation of hypersensitivity
responses in humans and in animal models upon priming with
FI-RSV (23), FI-MV (28), FI-parainfluenza virus 3 (24), a
formalin-inactivated mock antigen (2), RSV-G protein (22), or
dendritic cells cultured in fetal bovine serum (23a) and subse-
quent intratracheal challenge with the homologous antigens
suggests a common mechanism for these events. We hypothe-
size that this underlying mechanism is a systemic priming for
strong Th2 responses followed by an intrapulmonary recall,
largely irrespective of the nature of the antigen. The macaque
RSV model will allow the assessment of both the efficacy and
safety of candidate nonreplicating RSV vaccines before em-
barking on clinical trials in humans.
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